Yüklüyor......
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
Mutations of calreticulin (CALR) are detected in 25–30% of patients with essential thrombocythemia (ET) or primary myelofibrosis and cause frameshifts that result in proteins with a novel C-terminal. We demonstrate that CALR mutations activated signal transducer and activator of transcription 5 (STA...
Kaydedildi:
| Yayımlandı: | Leukemia |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5420793/ https://ncbi.nlm.nih.gov/pubmed/27807369 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.308 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|